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Abstract Darbepoetin alfa is a novel erythropoiesis-
stimulating protein with a two- to threefold longer half-
life than recombinant human erythropoietin (epoetin) in
adult patients with chronic kidney disease (CKD). This
randomized, open-label, crossover study was conducted
to determine the pharmacokinetic profile of darbepoetin
alfa in pediatric patients with CKD. Twelve patients
3–16 years of age with CKD were randomized and re-
ceived a single 0.5 µg/kg dose of darbepoetin alfa admin-
istered intravenously (IV) or subcutaneously (SC). After
a 14- to 16-day washout period, patients received an
identical dose of darbepoetin alfa by the alternate route.
After IV administration, the mean clearance of darbepoe-
tin alfa was 2.3 ml/h per kg, with a mean terminal half-
life of 22.1 h. After SC administration, absorption was
rate limiting, with a mean terminal half-life of 42.8 h and
a mean bioavailability of 54%. Comparison of these 
results with those from a previous study of darbepoetin
alfa in adult patients indicated that the disposition of 
darbepoetin alfa administered IV or SC is similar in
adult and pediatric patients, although absorption may be
slightly more rapid in pediatric patients after SC dosing.
The mean terminal half-life of darbepoetin alfa in this
study was approximately two- to fourfold longer than
that previously reported for epoetin in pediatric patients.
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Introduction
Recombinant human erythropoietin (epoetin) has been
shown to increase hemoglobin and reduce the need for
red blood cell transfusions in pediatric patients with
chronic kidney disease (CKD) [1, 2]. However, adminis-
tration of epoetin is often required two or three times
weekly, which can be a burden for younger patients and
their parents.
Previous work has indicated that there is a direct rela-
tionship between the degree of glycosylation, serum
half-life, and in vivo biological activity of epoetin [3].
Darbepoetin alfa [novel erythropoiesis-stimulating pro-
tein (NESP)] is a glycoprotein that was designed by in-
troducing five amino acid changes into the primary 
sequence of epoetin to create two additional N-linked
carbohydrate addition sites. Consequently, darbepoetin
alfa has five N-linked carbohydrate chains, whereas
epoetin has three. Although both molecules stimulate
erythropoiesis by the same mechanism, darbepoetin alfa
is biochemically distinct from epoetin, with a different
amino acid sequence and an increased molecular weight.
Results from a previous pharmacokinetic study of 
darbepoetin alfa conducted in adult patients with CKD
indicated that the terminal half-life of darbepoetin alfa
was approximately threefold longer than that of epoetin
after intravenous (IV) administration (25.3 h versus
8.5 h, respectively) and approximately twofold longer 
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after subcutaneous (SC) administration (48.8 h versus
24 h, respectively) [4, 5, 6]. However, the pharmacoki-
netic profile of darbepoetin alfa has not yet been evaluat-
ed in the pediatric population. This randomized, open-
label, crossover study was conducted to evaluate the




The protocol and consent form were approved by the institutional
review board for each study center, and written informed consent
was obtained from the parent, legal guardian, and patient (where
applicable) before initiation of study procedures. Patients
1–16 years of age with CKD who were receiving hemodialysis or
peritoneal dialysis or not yet receiving dialysis {glomerular filtra-
tion rate (GFR) <30 ml/min per 1.73 m2 as estimated by the
Schwartz formula [7, 8]} were enrolled at five study centers. 
Patients were receiving epoetin before the study, but had not re-
ceived epoetin within 7 days of the first injection of darbepoetin
alfa. Additional entry criteria included a hemoglobin concentra-
tion ≥9.0 g/dl and adequate iron stores (transferrin saturation
≥20%). Patients were excluded if they had uncontrolled hyperten-
sion (diastolic blood pressure >90 mmHg), elevated liver enzymes
(>2 times the upper limit of the normal range), hematological dis-
ease or hemoglobinopathies, or other disorders that could interfere
with the response to darbepoetin alfa or epoetin.
Study design
This was a randomized, open-label, crossover study. After a 
1-week screening period, eligible patients were randomized to re-
ceive a single 0.5-µg/kg dose of darbepoetin alfa administered IV
or SC. After a 14- to 16-day washout period, patients received an
identical dose of darbepoetin alfa by the alternate route. The ran-
domization was generated by computer program and was stratified
by age group (1–6, 7–11, and 12–16 years).
A darbepoetin alfa dose of 0.5 µg/kg was selected because it
allowed for a direct comparison with a previous pharmacokinetic
study of darbepoetin alfa conducted in adult patients with CKD
[4]. In addition, previous clinical experience with darbepoetin alfa
has indicated that doses of 0.45–0.75 µg/kg are safe and effective
for the treatment of anemia in the CKD population. Based on 
peptide mass, 0.5 µg/kg of darbepoetin alfa is approximately
equivalent to 100 U/kg of recombinant human erythropoietin.
IV doses were administered as a bolus within 15 s, and SC
doses greater than 1 ml in volume could be divided into two injec-
tions (delivered in rapid succession). A pre-dose blood sample for
the determination of baseline erythropoietin concentrations was
collected within 30 min of the first study drug administration. In
addition, a pre-dose blood sample was drawn on the day of the
second darbepoetin alfa injection for the determination of pre-dose
levels. For the evaluation of darbepoetin alfa pharmacokinetics 
after IV administration, blood samples were collected 5 min,
30 min, and 1, 2, 5, and 8 h after dosing, once between 24 and
48 h after dosing, once between 72 and 96 h after dosing, and at
168 h after dosing. After SC administration, blood samples were
collected 6, 24, 34, 48, 58, 72, and 96 h after dosing; 2 additional
samples were taken at least 16 h apart between 120 and 168 h after
dosing. Sample times for IV and SC dosing were optimized for
each route to ensure proper characterization of the individual pro-
files. Blood sample volumes were intentionally minimized (1.5 ml
per sample) for this pediatric population. As darbepoetin alfa is a
protein therapeutic, serum for measurement of possible antibody
formation to darbepoetin alfa was collected before each darbe-
poetin alfa dose and at the end of the study.
Pharmacokinetic analysis
Serum samples were analyzed using the Quantikine in vitro diag-
nostics epoetin alfa enzyme-linked immunosorbent assay (ELISA)
kit (R and D Systems, Minneapolis, Minn., USA). The standard
curve was constructed using darbepoetin alfa, and quality controls
ensured individual assay quality. In validation tests, the intra-assay
precision ranged from 1% to 4% for spiked samples and from 2%
to 4% for clinical serum samples. Interassay precision ranged from
5% to 7% for spiked samples. The assay range was 5 ng/ml (upper
limit of quantitation) to 0.078 ng/ml (lower limit of quantitation),
and the detection limit of the assay was 0.005 ng/ml. Serum con-
centrations of darbepoetin alfa were corrected for baseline endoge-
nous erythropoietin or epoetin concentrations (which cross-react
with the assay), as quantified against the darbepoetin alfa standard
curve, by direct subtraction. Cross-reactivity of recombinant hu-
man growth hormone in the ELISA was assessed at therapeutically
relevant concentrations and was verified to be negligible.
The pharmacokinetic analysis was performed using conven-
tional noncompartmental methods [9]. Single-dose pharmacoki-
netic parameters were estimated for each subject after both IV and
SC dosing, as appropriate. For estimation of the terminal phase, at
least the last three data points that consistently decreased and were
greater than or equal to twice the limit of quantitation in the darbe-
poetin alfa assay were included in the extrapolation. After IV dos-
ing, peak concentration at time zero (C0 by linear back-extrapola-
tion), initial volume of distribution (Vo=dose/Co), area under the
serum concentration-time curve from time zero to infinity (AUC),
clearance (CL=dose/AUC), terminal half-life (t1/2=ln 2/λz, where
λz is the terminal rate constant), and volume of distribution at
steady state (Vss) were calculated. After SC dosing, peak serum
concentration (Cmax ) and the time at which Cmax was observed
(Tmax), AUC, and t1/2 were estimated. Bioavailability (F=AUCSC/
AUCIV) after SC dosing was estimated for each subject for whom
both IV and SC profiles could be evaluated; if necessary, correc-
tions for dose changes were made.
Of the 12 patients who received both IV and SC darbepoetin
alfa, sufficient data were available for the extrapolation of 10 IV
and 8 SC concentration-time profiles. Extrapolation was not possi-
ble where five or fewer data points were available, or samples
were not collected beyond 72 h. For the 8 SC profiles for which
extrapolation could be performed, 7 IV profiles could also be fully
evaluated.
Results
Thirteen patients were randomized to the IV→SC group
(n=7) or the SC→IV group (n=6). One patient had a
GFR exceeding the inclusion criteria of <30 ml/min per
1.73 m2 and was withdrawn from the study before re-
ceiving darbepoetin alfa. Thus, pharmacokinetic samples
were collected for 12 patients (6 in each group). Demo-
graphic and baseline characteristics are presented for
these patients in Table 1. All patients had been receiving
epoetin before entry into the study.
A summary of noncompartmental pharmacokinetic
parameters after IV and SC administration of darbe-
poetin alfa is provided in Table 2 and Fig. 1. After IV 
administration, darbepoetin alfa serum concentrations
declined in a biphasic manner, with quantifiable concen-
trations up to at least 96 h after dosing. The mean (±SD)
terminal half-life was 22.1±4.8 h. The mean volume of
distribution at steady state was 80.9±32.5 ml/kg. 
After SC administration, darbepoetin alfa serum con-
centrations increased slowly to peak concentrations be-
tween 10 and 58 h after dosing (mean Tmax=36.2±
934
54%±14.3%. There were no safety concerns during the
study, and no antibody formation to darbepoetin alfa was
detected for any patient.
Discussion
This is the first report on the administration of darbe-
poetin alfa to pediatric patients with CKD. The results 
of this study indicate that the terminal half-life of darbe-
poetin alfa is approximately twofold longer after SC ad-
ministration than after IV administration in this patient
population. Exposure over time was approximately two-
fold higher with IV dosing than with SC dosing, result-
ing in an estimated bioavailability of 54% after SC 
administration.
The design of this study is similar to that of a previ-
ous pharmacokinetic study conducted in adult patients
with CKD [4], allowing a comparison of the pharmaco-
kinetic profile of darbepoetin alfa between the adult and
pediatric populations. In the adult study, patients re-
ceived a single IV dose of 0.5 µg/kg darbepoetin alfa or
100 U/kg epoetin and were crossed over to receive the
alternate therapy after a 28-day washout period. A subset
of patients also received a single SC dose of 0.5 µg/kg
darbepoetin alfa after an additional 28-day period. Over-
all, the mean half-life of darbepoetin alfa when adminis-
tered by IV or SC routes was similar in pediatric and
adult patients (Table 3 and Fig. 2). After SC administra-
tion, the mean bioavailability of darbepoetin alfa was
slightly higher in pediatric patients, and the earlier Tmax
suggests that darbepoetin alfa may be absorbed at a
slightly more rapid rate in pediatric patients compared
with adult patients after SC dosing. 
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Table 1 Patient demographic and baseline characteristics
Total patients (n=12)
Sex: male 6 (50%)








Peritoneal dialysis 1 (8%)
None 2 (17%)
Hemoglobin (g/dl)b 11.0 (9.1–13.4)
a Mean±SD
b Median (range)
Fig. 1 Mean (SD) baseline-corrected darbepoetin alfa serum 
concentration-time profiles after intravenous and subcutaneous 
administration (log scale). LOD Limit of detection
Table 2 Darbepoetin alfa noncompartmental pharmacokinetic 
parameters after intravenous and subcutaneous administration 
[t1/2 terminal half-life, C0 concentration at time zero (maximum IV
concentration), AUC(0-∞) area under the curve from zero to infinity,
V0 initial volume of distribution, VSS volume of distribution at
steady state, Tmax time to maximum concentration, Cmax maximum
concentration, VZ/F relative volume of distribution associated with
the terminal phase]
Parameter (units) Mean±SD n
IV administration
t1/2 (h) 22.1±4.8 10
C0 (ng/ml) 10.9±4.6 10
AUC(0-∞) (ng.h/ml) 233±56 10
V0 (ml/kg) 51.6±13.7 10
VSS (ml/kg) 80.9±32.5 10
Clearance (ml/h per kg) 2.3±0.6 10
SC administration
t1/2 (h) 42.8±23.0 8
Bioavailability (%) 54.2±14.3 7
Tmax (h) 36.2±14.1 10
Cmax (ng/ml) 1.3±0.6 10
AUC(0-∞) (ng.h/ml) 122±20 8
VZ/F (ml/kg) 268.3±144.7 8
Relative clearance (ml/h per kg) 4.3±0.6 8
14.1 h). The mean peak serum concentration of darbe-
poetin alfa after SC administration (Cmax=1.3±0.6 ng/ml)
was approximately eightfold lower than after IV admin-
istration (C0=10.9±4.6 ng/ml). However, serum concen-
trations were quantifiable for a longer period of time 
after SC dosing (approximately 168 h) than after IV dos-
ing (Fig. 1). The washout period of 14 days was suffi-
cient to allow concentrations to reduce to baseline 
values. Concentrations after SC administration declined
in a monophasic manner. The mean terminal half-life of
darbepoetin alfa after SC administration (42.8±23.0 h)
was approximately twofold longer than after IV adminis-
tration, indicating that there is ongoing darbepoetin alfa
absorption during this interval, and absorption may be
rate limiting. Exposure to darbepoetin alfa, as measured
by AUC(0-∞), was approximately twofold lower after 
SC administration than after IV administration, and the 
estimated mean bioavailability after SC dosing was
These results are consistent with previous pharmaco-
kinetic studies conducted in pediatric patients receiving
epoetin. Previous reports indicated that the mean termi-
nal half-life of epoetin after IV administration to pediat-
ric patients ranged from 5.6 to 10.9 h, with mean clear-
ance values ranging from 6 to 10.1 ml/h per kg [10, 11,
12, 13]. After SC dosing, absorption was rate limiting,
such that the mean terminal half-life ranged from 13.3 to
25.2 h, with bioavailability estimates ranging from 33%
to 40% [10, 13, 14, 15]. Due to the wide range in values,
comparison with literature estimates for adults is diffi-
cult. However, Evans et al. [10] concluded that, after IV
dosing in pediatric patients, clearance was increased
twofold and terminal half-life decreased by 30% to 86%
compared with adults, and after SC dosing, bioavailabili-
ty was increased twofold. Geva and Sherwood [11],
however, concluded that the pharmacokinetics of epoetin
in pediatric patients were similar to that of adults. Thus,
the findings in the current study are similar to observa-
tions for epoetin with regard to the pharmacokinetics of
darbepoetin alfa in children and adults.
The mean terminal half-life of darbepoetin alfa in this
study was 42.8 h after SC administration and 22.1 h after
IV administration, approximately two- to fourfold longer
than the half-life of epoetin (SC 21.1 h, IV 5.6 h) in pe-
diatric patients from a previous study [10]. Thus, the
pharmacokinetic profile of darbepoetin alfa may allow
for less frequent dosing relative to epoetin. In adult 
patients with CKD who were receiving dialysis, darbe-
poetin alfa administered IV once weekly maintained 
hemoglobin concentrations as effectively as epoetin 
administered IV three times weekly [16]. In addition, a
randomized, comparative study of darbepoetin alfa and
epoetin administered IV or SC found that 95% of dialy-
sis patients who were receiving epoetin once weekly at
baseline successfully maintained stable hemoglobin con-
centrations when switched to darbepoetin alfa adminis-
tered once every 2 weeks [17].
The results of this single-dose study indicate that the
pharmacokinetic profile of darbepoetin alfa administered
IV or SC in pediatric patients with CKD is similar to that
of adults, although the absorption of darbepoetin alfa
may be slightly more rapid in pediatric patients after SC
administration. A study to evaluate the efficacy and safe-
ty of darbepoetin alfa in pediatric patients is currently
underway.
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